bioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests

Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecasts

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath® Lung to patients since Jan. 1, 2024. CyPath® Lung is a noninvasive test to detect early-stage lung cancer.